Oncology

Liver cancer
#AACR 2023 #Cancer research #Cancer treatment #Liver cancer #Oncology #Phase III trial

Results revealed for ‘practice-changing’ combination liver cancer therapy

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023,… Read More

#Cancer Research #News

#AACR 2023 #Cancer research #Cancer vaccine #mRNA #mRNA-based vaccines #Oncology

Personalised mRNA cancer vaccine prolongs survival in melanoma

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb… Read More

#Cancer Research #News #Trending News

#AACR 2023 #Cancer #Cancer immunotherapy #Cancer research #Oncology #Therapeutics

Eight announcements to expect at AACR 2023   

The American Association for Cancer Research (AACR) Annual Meeting is taking place at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023. As the theme, Advancing the Frontiers of Cancer Science and Medicine, suggests, a number of announcements, results and presentations will take place… Read More

#News

Applause
#AACR #AACR 2023 #Awards #Cancer research #Clinical research #Oncology

Who are the AACR Scientific Achievement Award winners?

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. Carl H June, MD, FAACR – Lifetime Achievement in Cancer Research June, a Fellow of… Read More

#Exclusive Content

Proteomics
#Genetics / genomics #Mass spectrometry / NMR #Nautilus #Oncology #Protein chemistry / Proteomics #Rare cancers

Democratising proteomics for cancer and beyond

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick, about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. At… Read More

#Exclusive Content #Trends & Analysis

#Cancer research #Drug discovery #IRBM #Oncology #Rare cancers

Reshaping rare cancer drug discovery

This paid-for advertorial by IRBM appeared in DDW Volume 24 – Issue 2, Spring 2023 The landscape for treating rare cancers is changing with advances in molecular genetics, novel drug modalities and patient-derived models. Dr Alessandro Carugo, IRBM, explains how building unique drug discovery strategies and expert… Read More

#Exclusive Content

#Drug discovery #Immunotherapy #Oncology

Latest DDW Guide: Exclusive insight into cancer research

DDW has published the latest addition to its Guide Series, ‘Find out about the global breakthroughs, opportunities and developments in cancer research.’ It is sponsored by IRBM. In this free, exclusive guide, you will learn more about: Where the global breakthroughs, opportunities and developments are in cancer research Why cancer-associated… Read More

#News

#Cancer research #Clinical research #Clinical trial #Drug discovery #Oncology #Phase I trial #Phase II trial

Podcast shares industry highlights for 3-7 April

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headlines this week have revealed a high level of clinical trial activity taking place… Read More

#News

Genetic sequencing in the laboratory
#Cancer research #Genetics / genomics #Next generation sequencing #Oncology #Personalised medicine #RNA sequencing #The Tecan Group #Webinar

Webinar: Find out how NGS is informing oncology drug discovery

Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space. Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST… Read More

Webinar date:
Brought to you by Tecan
#News

#Cancer research #Clinical research #Clinical trial #Drug discovery #Oncology #Phase I trial #Phase II trial

This week in drug discovery (3-7 April)

News round-up for 3-7 April by DDW Digital Content Editor Diana Spencer.  The headlines this week have revealed a high level of clinical trial activity taking place internationally. In just the last few days, new clinical trials in colorectal cancer, osteoarthritis, and brain cancer have been launched,… Read More

#News

Computer in laboratory
#Cancer research #Funding #Investment #Mosaic Therapeutics #Oncology #Wellcome Sanger Institute

Company raises $28m to develop targeted cancer therapies

Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many… Read More

#News #Regulatory #Trending News

Cancer patient receives chemotherapy via IV
#Avacta #Cancer research #Clinical trial #Oncology #Phase I trial #Solid tumours

Avacta increases dose of AVA6000 in solid tumours study

Avacta Group has dosed its first patient in the fifth cohort of the first-in-human Phase I trial (ALS-6000-101) of AVA6000 in solid tumours. This follows the approval of an amended clinical trial protocol by the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to allow for… Read More

#Cancer Research #News

Pancreatic cancer concept
#Biotechnology #Cancer research #Drug development #Drug discovery #Gene therapy #Oncology

How this biotech is looking to collaboration to treat pancreatic cancer

DDW Editor Reece Armstrong speaks to Howard Davis, CEO of clinical stage oncology company, Akamis Bio, about its work in developing a gene therapy to treat pancreatic cancer.    In February this year, Akamis Bio announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to… Read More

#Exclusive Content

Telecommunications network North America
#Cancer research #Collaboration #Drug discovery #IRBM #Italy #Oncology #United States

Only non-US company joins cancer drug discovery consortium

Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The CBC is the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered… Read More

#Cancer Research #News

Cancer research
#Animal models #Cancer research #Cancer treatment #Oncology #The Institute of Cancer Research

First-in-class HSF1 pathway drug shrinks tumours in mice

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was… Read More

#Cancer Research #News